HER-2 positivity, therefore, resolves a specific treatment decision in a specific decision model: HER-2 does not resolve the treatment decisions in a “hot and shaky” patient or in a torn anterior cruciate ligament, or even in the selection of alternatives to Herceptin in a HER-2 positive breast cancer. Here, ERBB2 is linked to breast cancer.